Advertising Approval Requirements for Medical Devices in Egypt: EDA Written Approval Rule

1. Key takeaways

Egypt applies a pre-approval regime to medical device advertising: no medical device advertisement may be published on any media channel without the written approval of the competent administration of the EDA. At the same time, the EDA has stated explicitly that its website and official pages are the sole official source for advertising violations lists. For companies, these two rules together form the compliance baseline for device promotion in Egypt: obtain approval first, publish second; and verify any violation claim on the official website only.

2. Legal basis

The approval requirement, the promotional sample rules and the violations-list declaration rest on the following sources.

3. Expert insights

Insight 1: the provision uses the words any media outlet, leaving no exceptions in scope.

The original wording of Section 11, item 8 is any media outlet. Television, print, outdoor media, social media, short-video platforms, corporate websites and e-commerce pages all fall, in principle, within coverage. When running digital marketing in Egypt, companies cannot assume that an online-only poster or post falls outside the definition of advertising.

Insight 2: the approving body is the competent administration, not the EDA in the abstract.

The provision refers to the competent administration of the Egyptian Drug Authority. Before submitting an approval application, companies must confirm which specific administrative department has jurisdiction over their channel. The same logic applies as for registration (local or import) and variation intake: identify the correct desk first, then file.

Insight 3: the uniqueness declaration on violations lists is a proactive risk warning from the EDA.

In a website news item the EDA stated that its website and official pages are the sole official source for advertising violations lists. The practical meaning is that screenshots of violations lists circulating in the market, third-party reposts and social media rankings have no official effect. To verify whether the company itself or a competitor has been named, check the EDA website directly.

Insight 4: marketing samples and advertising approval are two independent regulatory lines.

GL.CAMD.007 Section 8, item 4 provides that only the Scientific Office may import samples for advertising and marketing purposes; the samples must be marked as advertising samples and not for sale, are checked by the Central Administration for Pharmaceutical Establishments Inspection, and require the full set of quality certificates according to device classification. In other words, obtaining approval of advertising content does not equal permission to import promotional samples; the latter carries separate eligibility and marking requirements.

Insight 5: advertising compliance and labelling compliance constrain each other in content.

The labelling guideline (published 2022) requires that label information be readable and understandable by medical professionals and by ordinary Egyptian citizens. If advertising content is inconsistent with the intended purpose and indications as stated on the label or in the instructions for use, it can simultaneously trigger an advertising violation and a labelling change issue. Any restatement of the intended purpose falls under the Tell, Assess and then Do category of variations in GL.CAMD.003, requiring suspension of marketing and an assessment of whether the product constitutes a new device.

Insight 6: dosage-form devices carry higher advertising risk.

GL.CAMD.002 Section 5 provides that when a dosage-form device comes to market, the committee evaluates three matters: safety and effectiveness; prescription versus OTC status; and the claims on the label against the intended purpose in the instructions for use. The third item directly addresses claim wording and echoes the advertising approval requirement: the more aggressive the claim, the higher the risk at both committee review and advertising approval.

Insight 7: advertising violations affect the company’s overall compliance standing.

Although the provisions do not directly link advertising violations to registration eligibility, read together with Section 11, item 9 (foreign manufacturers and importers bear full responsibility for effectiveness and technical safety) and the Section 8 vigilance reporting duty, an advertising violation record enters the company’s overall compliance profile and can materially influence subsequent re-registration and variation outcomes. As a practical estimate, the exact interaction mechanisms follow the EDA’s current rules.

4. Practical recommendations

The following controls keep promotional activity inside the approval perimeter.

1. Obtain written approval before publishing on any channel, including online and social media.
2. Identify the competent administration before submitting the approval application.
3. Verify violation information only on the EDA website and official pages, never through third-party reposts.
4. Route promotional samples through the Scientific Office, marked as advertising samples and not for sale.
5. Check advertising copy word for word against the label and instructions for use to avoid triggering a Tell, Assess variation.
6. Run a committee review risk assessment in advance for dosage-form device claims.
7. File advertising approval documents in the compliance archive for citation at re-registration and variation.

5. Verification checklist

• □ Content intended for publication has obtained written approval from the competent administration of the EDA
• □ The competent administration has been identified
• □ All publication channels (including online and social media) are covered by the approval scope
• □ The verification channel for violation information is locked to the EDA website and official pages
• □ Promotional samples are imported by the Scientific Office and marked as advertising samples, not for sale
• □ Advertising copy matches the intended purpose wording of the label and instructions for use
• □ A committee review risk assessment has been performed for dosage-form device claims
• □ Advertising approval documents are archived

Regulatory information verified as of October 29, 2026. The advertising approval requirements in this article follow EDREX: GL.CAMD.002 Version 2, Section 11, general requirement item 8; promotional sample rules follow EDREX: GL.CAMD.007 Version 2, Section 8, item 4; the sole-source declaration follows current EDA website news.

• Egypt local support: GRZAN assists manufacturers from the Chinese mainland and overseas with EDA medical device registration, import approval and variation applications, including registration applicant pathway design (importing company, local factory, or Scientific Office), preparation for Scientific Committee evaluation, demonstration of free sale certificate routes from reference countries, Arabic labelling and instructions-for-use localization, and the setup of vigilance and periodic reporting systems.
• Service capabilities: product classification and risk grading (devices Class I–III, IVD Class A–D), registration and re-registration, applicability assessment for system registration and bundled registration, three-way variation classification, import approval and annual import plans, and support for vigilance reporting and field safety corrective actions.
• Contact: hito.lin@grzan.cn; website www.grzan.cn.